Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Medivir AB - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Medivir AB - Product Pipeline Review - 2014', provides an overview of the Medivir AB's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Medivir AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Medivir AB including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Medivir AB's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Medivir AB's pipeline products Reasons to buy - Evaluate Medivir AB's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Medivir AB in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Medivir AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Medivir AB and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Medivir AB - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Medivir AB and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Medivir AB Snapshot 5 Medivir AB Overview 5 Key Information 5 Key Facts 5 Medivir AB - Research and Development Overview 6 Key Therapeutic Areas 6 Medivir AB - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Medivir AB - Pipeline Products Glance 15 Medivir AB - Clinical Stage Pipeline Products 15 Phase I Products/Combination Treatment Modalities 15 Medivir AB - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Medivir AB - Drug Profiles 18 MIV-711 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MIV-150 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 MIV-247 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 MIV-710 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule to Inhibit HCV Polymerase for Hepatitis C 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit NS5B Nucleotide Polymerase for Hepatitis C 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule to Inhibit Renin for Hypertension 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecule to Inhibit HIV Protease for HIV Infection 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule to Inhibit NS3 Protease for Dengue 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Inhibit Fusion Protein for RSV Infections 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit Proteases for Infectious Diseases 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Medivir AB - Pipeline Analysis 30 Medivir AB - Pipeline Products by Target 30 Medivir AB - Pipeline Products by Route of Administration 31 Medivir AB - Pipeline Products by Molecule Type 32 Medivir AB - Pipeline Products by Mechanism of Action 33 Medivir AB - Recent Pipeline Updates 34 Medivir AB - Dormant Projects 36 Medivir AB - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 lagociclovir 37 MIV-150 37 MIV-701 37 Small Molecule to Inhibit BACE for Alzheimer Disease 37 Small Molecule to Inhibit NS5A for Hepatitis C 38 TMC-649128 38 Medivir AB - Locations And Subsidiaries 39 Head Office 39 Other Locations & Subsidiaries 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables Medivir AB, Key Information 5 Medivir AB, Key Facts 5 Medivir AB - Pipeline by Indication, 2014 8 Medivir AB - Pipeline by Stage of Development, 2014 9 Medivir AB - Monotherapy Products in Pipeline, 2014 10 Medivir AB - Partnered Products in Pipeline, 2014 11 Medivir AB - Partnered Products/ Combination Treatment Modalities, 2014 12 Medivir AB - Out-Licensed Products in Pipeline, 2014 13 Medivir AB - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Medivir AB - Phase I, 2014 15 Medivir AB - Preclinical, 2014 16 Medivir AB - Discovery, 2014 17 Medivir AB - Pipeline by Target, 2014 30 Medivir AB - Pipeline by Route of Administration, 2014 31 Medivir AB - Pipeline by Molecule Type, 2014 32 Medivir AB - Pipeline Products by Mechanism of Action, 2014 33 Medivir AB - Recent Pipeline Updates, 2014 34 Medivir AB - Dormant Developmental Projects,2014 36 Medivir AB - Discontinued Pipeline Products, 2014 37 Medivir AB, Other Locations 39 Medivir AB, Subsidiaries 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
